January 2019 - Cancer Currents Blog
-
Glioblastoma Study Highlights Sex Differences in Brain CancerMen and women with glioblastoma appear to respond differently to standard treatment. A new study identifies biological factors that might contribute to this sex difference.
-
African American Men More Likely to Die from Low-Grade Prostate CancerFor African American men, the risk of dying from low-grade prostate cancer is double that of men of other races, a new study has found. But, despite the increase, the risk is still small.
-
Managing Cancer Pain: Are Better Approaches on the Horizon?Pain is a common and much-feared symptom among people with cancer and long-term survivors. As more people survive cancer for longer periods, there is a renewed interest in developing new, nonaddictive approaches for managing their chronic pain.
-
Immunotherapy Effective in Alveolar Soft Part SarcomaPeople with advanced alveolar soft part sarcoma (ASPS), a rare cancer, appear to benefit from a type of immunotherapy called an immune checkpoint inhibitor, according to results from a small clinical trial.
-
Atezolizumab Approved for Initial Treatment of Metastatic Lung CancerOn December 6, 2018, the Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a standard three-drug regimen as an initial treatment for advanced lung cancer that does not have EGFR or ALK mutations.
-
For Early-Stage Lung Cancer, Study Identifies Potential New Biomarker, Treatment TargetA new study has identified a potential biomarker of early-stage non–small cell lung cancer (NSCLC). The biomarker, the study’s leaders said, could help diagnose precancerous lung growths and early-stage lung cancers noninvasively and distinguish them from noncancerous growths.